Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease
Hand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2020
|
| _version_ | 1797076458630283264 |
|---|---|
| author | Nguyet, LA Thanh, TT Nhan, LNT Hong, NTT Nhu, LNT Van, HMT Ny, NTH Anh, NT Han, DDK Tuan, HM Huy, VQ Viet, HL Cuong, HQ Thao, NTT Viet, DC Khanh, TH Thwaites, L Clapham, H Hung, NT Chau, NVV Thwaites, G Ha, DQ van Doorn, HR Tan, LV |
| author_facet | Nguyet, LA Thanh, TT Nhan, LNT Hong, NTT Nhu, LNT Van, HMT Ny, NTH Anh, NT Han, DDK Tuan, HM Huy, VQ Viet, HL Cuong, HQ Thao, NTT Viet, DC Khanh, TH Thwaites, L Clapham, H Hung, NT Chau, NVV Thwaites, G Ha, DQ van Doorn, HR Tan, LV |
| author_sort | Nguyet, LA |
| collection | OXFORD |
| description | Hand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after the onset of illness from HFMD patients infected with enterovirus A71 (EV-A71), coxsackievirus A (CVA) 6, CVA10, and CVA16 to study cross neutralization. For homotypic viruses, seropositivity increased from <60% at enrollment to 97%–100% at follow-up, corresponding to seroconversion rates of 57%–93%. Seroconversion for heterotypic viruses was recorded in only 3%–23% of patients. All plasma samples from patients infected with EV-A71 subgenogroup B5 could neutralize the emerging EV-A71 subgenogroup C4. Collectively, our results support previous reports about the potential benefit of EV-A71 vaccine but highlight the necessity of multivalent vaccines to control HFMD. |
| first_indexed | 2024-03-07T00:04:04Z |
| format | Journal article |
| id | oxford-uuid:76f35157-12a4-41e2-998f-1cf157e7354c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:04:04Z |
| publishDate | 2020 |
| publisher | Centers for Disease Control and Prevention |
| record_format | dspace |
| spelling | oxford-uuid:76f35157-12a4-41e2-998f-1cf157e7354c2022-03-26T20:19:55ZNeutralizing antibodies against enteroviruses in patients with hand, foot and mouth diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:76f35157-12a4-41e2-998f-1cf157e7354cEnglishSymplectic ElementsCenters for Disease Control and Prevention2020Nguyet, LAThanh, TTNhan, LNTHong, NTTNhu, LNTVan, HMTNy, NTHAnh, NTHan, DDKTuan, HMHuy, VQViet, HLCuong, HQThao, NTTViet, DCKhanh, THThwaites, LClapham, HHung, NTChau, NVVThwaites, GHa, DQvan Doorn, HRTan, LVHand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after the onset of illness from HFMD patients infected with enterovirus A71 (EV-A71), coxsackievirus A (CVA) 6, CVA10, and CVA16 to study cross neutralization. For homotypic viruses, seropositivity increased from <60% at enrollment to 97%–100% at follow-up, corresponding to seroconversion rates of 57%–93%. Seroconversion for heterotypic viruses was recorded in only 3%–23% of patients. All plasma samples from patients infected with EV-A71 subgenogroup B5 could neutralize the emerging EV-A71 subgenogroup C4. Collectively, our results support previous reports about the potential benefit of EV-A71 vaccine but highlight the necessity of multivalent vaccines to control HFMD. |
| spellingShingle | Nguyet, LA Thanh, TT Nhan, LNT Hong, NTT Nhu, LNT Van, HMT Ny, NTH Anh, NT Han, DDK Tuan, HM Huy, VQ Viet, HL Cuong, HQ Thao, NTT Viet, DC Khanh, TH Thwaites, L Clapham, H Hung, NT Chau, NVV Thwaites, G Ha, DQ van Doorn, HR Tan, LV Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease |
| title | Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease |
| title_full | Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease |
| title_fullStr | Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease |
| title_full_unstemmed | Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease |
| title_short | Neutralizing antibodies against enteroviruses in patients with hand, foot and mouth disease |
| title_sort | neutralizing antibodies against enteroviruses in patients with hand foot and mouth disease |
| work_keys_str_mv | AT nguyetla neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT thanhtt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT nhanlnt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT hongntt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT nhulnt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT vanhmt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT nynth neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT anhnt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT handdk neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT tuanhm neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT huyvq neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT viethl neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT cuonghq neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT thaontt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT vietdc neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT khanhth neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT thwaitesl neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT claphamh neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT hungnt neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT chaunvv neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT thwaitesg neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT hadq neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT vandoornhr neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease AT tanlv neutralizingantibodiesagainstenterovirusesinpatientswithhandfootandmouthdisease |